PPT-CROI 2016

P de Truchis Nouvelles molécules Combinectine deux adnectines antiCD4 et antigp41 associées à un peptide inhibiteur de fusion cet inhibiteur dentrée a une longue durée daction et ses composants bloquent lentrée du VIH dans les cellules de façon synergique. Nina Kim, MD . Associate Professor of Medicine. Division of Allergy & Infectious Diseases. University of Washington. No financial conflicts of interest. ION-4. Ledipasvir-Sofosbuvir. for 12 weeks. P de Truchis. Nouvelles molécules. . Combinectine. : deux . adnectines. anti-CD4 et anti-gp41 associées à un peptide inhibiteur de fusion :. cet inhibiteur d’entrée a une longue durée d’action et ses composants bloquent l’entrée du VIH dans les cellules de façon synergique. Weill Cornell Medicine. New York, New York. Investigational . Antiretroviral Drugs. FORMATTED. : . 01-13-17. New York, New York: February 24, 2017 . Learning Objectives. After attending this presentation. Weill Cornell Medicine. New York, New York. Investigational . Antiretroviral Drugs. FORMATTED. : . 01-13-17. New York, New York: February 24, 2017 . Learning Objectives. After attending this presentation. Joseph J. Eron, Jr, MD Professor of Medicine and Epidemiology The University of North Carolina at Chapel Hill Chapel Hill, North Carolina Future Directions: Investigational Approaches to Antiretroviral Therapy New Drugs in Development Are We Ready for Long-Acting ART? Melanie A. Thompson, MD AIDS Research Consortium of Atlanta Follow me on Twitter @ drmt Financial Relationships With Commercial Entities Dr Thompson's institution has received grants for research from Bristol-Myers Squibb, CytoDyn, Inc, Frontier Biotechnologies, Gilead Sciences, Inc, GlaxoSmithKline, Joseph J. Eron, Jr, MD. Professor of Medicine. University of North Carolina. Chapel Hill, North Carolina. Financial Relationships With Commercial Entities. Dr Eron has served as an ad hoc consultant to Janssen, ViiV Healthcare, Merck, and Gilead Sciences, Inc. His institution receives contracts for clinical research on which Dr Eron is the local principal investigator from Janssen Therapeutics, ViiV Healthcare, and Gilead Sciences, Inc. Résumé scientifique des principales études cliniques présentées à la CROI 2019. CAHR is pleased to provide this scientific summary of the major clinical studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019). The synthesis aims to improve the cascade of care by increasing the skills and knowledge of Canadian health care professionals working in the realm of HIV. This presentation was made possible with the support of an educational grant from ViiV Healthcare.. Prediction. . of . events. . after. ART. initiation. INSTI . and IRIS ?. Test and . Treat. Same. Day. Switch DTG/ABC/3TC. to BIC/F/TAF. Miscellaneous. ART. Test and Treat the Same Day - Is this feasible ?. Shireesha Dhanireddy. Robert Harrington. March 17, 2014. No financial conflicts of interest. Outline. Treatment Studies. Tenofovir. . alafenamide. (TAF) in a single-tablet regimen in initial HIV-1 infection . CROI Update 2016. FORMATTED: MM/DD/YY. From . H . Masur. , MD, . at Washington, DC: April 15, 2016, IAS-USA. . Oral Abstract. Estimating the Lifetime Risk of HIV Infection in the United States. Kristen Hess et al. Judith S. Currier, MD, MSc. Professor of Medicine. University of California Los Angeles. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. Jeffrey Lennox, MD. Professor of Medicine. Emory University. Atlanta. , Georgia. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. AND OPPORTUNISTIC INFECTIONS. (CROI 2020). BOSTON| 8-11 MARCH 2020. Faculty. Pedro . Cahn. , Buenos-Aires, Argentina. Anton . Pozniak. , London, UK. François . Raffi. , Nantes, France. This presentation is made in complete editorial freedom .